Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

The kinase Mirk is a potential therapeutic target in osteosarcoma.

Yang C, Ji D, Weinstein EJ, Choy E, Hornicek FJ, Wood KB, Liu X, Mankin H, Duan Z.

Carcinogenesis. 2010 Apr;31(4):552-8. doi: 10.1093/carcin/bgp330. Epub 2009 Dec 30.

2.

The kinase Mirk/Dyrk1B mediates cell survival in pancreatic ductal adenocarcinoma.

Deng X, Ewton DZ, Li S, Naqvi A, Mercer SE, Landas S, Friedman E.

Cancer Res. 2006 Apr 15;66(8):4149-58.

3.

Lentiviral shRNA screen of human kinases identifies PLK1 as a potential therapeutic target for osteosarcoma.

Duan Z, Ji D, Weinstein EJ, Liu X, Susa M, Choy E, Yang C, Mankin H, Hornicek FJ.

Cancer Lett. 2010 Jul 28;293(2):220-9. doi: 10.1016/j.canlet.2010.01.014. Epub 2010 Feb 9.

PMID:
20144850
4.

Mirk/Dyrk1b mediates cell survival in rhabdomyosarcomas.

Mercer SE, Ewton DZ, Shah S, Naqvi A, Friedman E.

Cancer Res. 2006 May 15;66(10):5143-50.

5.

Cyclin G-associated kinase is necessary for osteosarcoma cell proliferation and receptor trafficking.

Susa M, Choy E, Liu X, Schwab J, Hornicek FJ, Mankin H, Duan Z.

Mol Cancer Ther. 2010 Dec;9(12):3342-50. doi: 10.1158/1535-7163.MCT-10-0637. Epub 2010 Sep 29.

6.
7.

Mirk/dyrk1B is a Rho-induced kinase active in skeletal muscle differentiation.

Deng X, Ewton DZ, Pawlikowski B, Maimone M, Friedman E.

J Biol Chem. 2003 Oct 17;278(42):41347-54. Epub 2003 Aug 5.

8.
9.

Systematic kinome shRNA screening identifies CDK11 (PITSLRE) kinase expression is critical for osteosarcoma cell growth and proliferation.

Duan Z, Zhang J, Choy E, Harmon D, Liu X, Nielsen P, Mankin H, Gray NS, Hornicek FJ.

Clin Cancer Res. 2012 Sep 1;18(17):4580-8. doi: 10.1158/1078-0432.CCR-12-1157. Epub 2012 Jul 12.

10.

The survival kinase Mirk/Dyrk1B is a downstream effector of oncogenic K-ras in pancreatic cancer.

Jin K, Park S, Ewton DZ, Friedman E.

Cancer Res. 2007 Aug 1;67(15):7247-55.

11.

Construction of conditional lentivirus-mediated shRNA vector targeting the human Mirk gene and identification of RNAi efficiency in rhabdomyosarcoma RD cells.

Zhao B, Yang C, Yang S, Gao Y, Wang J.

Int J Oncol. 2013 Oct;43(4):1253-9. doi: 10.3892/ijo.2013.2048. Epub 2013 Aug 2.

PMID:
23913162
12.

Mirk/dyrk1B decreases the nuclear accumulation of class II histone deacetylases during skeletal muscle differentiation.

Deng X, Ewton DZ, Mercer SE, Friedman E.

J Biol Chem. 2005 Feb 11;280(6):4894-905. Epub 2004 Nov 16.

13.

Mirk/Dyrk1B, a novel therapeutic target, mediates cell survival in non-small cell lung cancer cells.

Gao J, Zheng Z, Rawal B, Schell MJ, Bepler G, Haura EB.

Cancer Biol Ther. 2009 Sep;8(17):1671-9. Epub 2009 Sep 20.

14.

The survival kinase Mirk/dyrk1B is activated through Rac1-MKK3 signaling.

Jin K, Lim S, Mercer SE, Friedman E.

J Biol Chem. 2005 Dec 23;280(51):42097-105. Epub 2005 Oct 27.

15.

Functional genome screen for therapeutic targets of osteosarcoma.

Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T.

Cancer Sci. 2009 Dec;100(12):2268-74. doi: 10.1111/j.1349-7006.2009.01310.x. Epub 2009 Aug 10.

16.
17.

The involvement of FoxO in cell survival and chemosensitivity mediated by Mirk/Dyrk1B in ovarian cancer.

Gao J, Yang X, Yin P, Hu W, Liao H, Miao Z, Pan C, Li N.

Int J Oncol. 2012 Apr;40(4):1203-9. doi: 10.3892/ijo.2011.1293. Epub 2011 Dec 12.

19.

VEGF-siRNA silencing induces apoptosis, inhibits proliferation and suppresses vasculogenic mimicry in osteosarcoma in vitro.

Mei J, Gao Y, Zhang L, Cai X, Qian Z, Huang H, Huang W.

Exp Oncol. 2008 Mar;30(1):29-34.

PMID:
18438338
20.

Supplemental Content

Support Center